{"id":"NCT02545868","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis","officialTitle":"A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-27","primaryCompletion":"2017-02-14","completion":"2021-09-21","firstPosted":"2015-09-10","resultsPosted":"2018-06-06","lastUpdate":"2024-03-26"},"enrollment":102,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"BIOLOGICAL","name":"23-PPV","otherNames":[]},{"type":"BIOLOGICAL","name":"13-PCV Booster","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"KLH","otherNames":[]},{"type":"DRUG","name":"OCR","otherNames":["RO4964913, PRO70769, rhuMAb 2H7"]},{"type":"BIOLOGICAL","name":"TT Vaccine","otherNames":[]}],"arms":[{"label":"Group A: OCR + Vaccines","type":"EXPERIMENTAL"},{"label":"Group B: Vaccines (Optional OCR in Extension)","type":"OTHER"}],"summary":"This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \\[TT\\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \\[23-PPV\\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \\[13-PCV\\], influenza vaccine, keyhole limpet hemocyanin \\[KLH\\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).","primaryOutcome":{"measure":"Percentage of Participants With Positive Response to TT Vaccine Measured 8 Weeks After TT Vaccine","timeFrame":"8 weeks after TT vaccine","effectByArm":[{"arm":"Group A (A1 + A2)","deltaMin":23.9,"sd":null},{"arm":"Group B","deltaMin":54.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":22,"countries":["United States","Canada"]},"refs":{"pmids":["32727835"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":33},"commonTop":["INFUSION RELATED REACTION","UPPER RESPIRATORY TRACT INFECTION","FATIGUE","URINARY TRACT INFECTION","HEADACHE"]}}